神経性無食欲症市場 - 市場の洞察、疫学、市場予測：2034年

2023年の主要7ヶ国における神経性無食欲症治療の市場規模は約6,000万米ドルで、そのうち米国が約3,000万米ドルを占めました。メディアや文化におけるやせ志向や理想化された身体イメージの社会的強調は、予測期間（2024年～2034年）において、神経性無食欲症を含む身体への不満や乱れた食行動の一因となり得ます。

専門的な治療プログラムや治療を含むメンタルヘルス・サービスへのアクセスが改善した結果、神経性無食欲症の診断を受ける人が増える可能性があります。さらに、診断基準やスクリーニング方法の改善とともに摂食障害に対する認識が高まることで、予測期間中（2024～2034年）に神経性無食欲症の患者をより正確に特定することができます。

人口の増加、高齢化、人口動態の変化などの要因別、神経性無食欲症に罹患する人の数が増加し、それによって治療オプションの潜在的な市場規模が拡大する可能性があります。神経性無食欲症の現在の治療には、身体的側面と心理的側面の両方に対処する集学的アプローチが必要であり、この疾患に取り組もうとしている企業はほとんどありません。世界中で神経性無食欲症の症例が増加していることから、症状を抑えるだけでなく、この障害を治癒させる薬理学的治療が非常に必要とされています。

神経性無食欲症は、成長期の子供の体重減少や適切な体重増加の欠如、身長や身長に見合った適切な体重を維持することの困難さ、そして多くの人のボディ・イメージを特徴とする摂食障害です。神経性無食欲症の患者は一般に、食べるカロリーや食品の種類を制限します。

この疾患は、患者自身による意図的な体重減少を特徴とします。思春期の少女や若い女性に最もよくみられますが、思春期の少年や若い男性も罹患することがあります。この疾患は特異的な精神病理学と関連しており、太ることへの恐怖や体の輪郭の弛緩が、侵入的な過大評価として持続し、患者は自分自身に低い体重の閾値を課します。通常、二次的な内分泌および代謝の変化と身体機能の障害を伴う、さまざまな重症度の低栄養がみられます。食欲抑制剤や利尿剤の使用による過度の運動誘発性の嘔吐や瀉下などの症状があります。

当レポートでは、主要7ヶ国における神経性無食欲症市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2034年までの市場規模予測、および医療のアンメットニーズなどを提供しています。

目次

第1章 重要な洞察

第2章 レポートのイントロダクション

第3章 神経性無食欲症市場概要

第4章 神経性無食欲症市場：将来の展望

第5章 神経性無食欲症のエグゼクティブサマリー

第6章 疾患の背景と概要：神経性無食欲症（AN）

• 神経性無食欲症のイントロダクション
• 神経性無食欲症の種類
• 神経性無食欲症のリスク要因
• 神経性無食欲症の症状
• 神経性無食欲症の合併症
• 神経性無食欲症の病因
• 神経性無食欲症の病態生理学
• 神経性無食欲症の診断アプローチ
• 神経性無食欲症の治療と管理

第7章 疫学と患者人口

• 主な調査結果
• 疫学の調査手法
• 前提と根拠：主要7ヶ国
• 主要7ヶ国における神経性無食欲症の総罹患数
• 主要7ヶ国における神経性無食欲症の診断済み有病者総数
• 米国
• 欧州主要5ヶ国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
• 日本

第8章 患者動向

第9章 新興薬剤

第10章 神経性無食欲症：主要7ヶ国分析

• 主な調査結果
• 拒食症市場の調査手法
• 市場見通し
• 属性分析
• 主要な市場予測の前提条件
• 主要7ヶ国における拒食症の総市場規模
• 主要7ヶ国における拒食症の治療薬別市場規模
• 米国における拒食症の総市場規模
• ドイツにおける拒食症の治療薬別市場規模

第11章 主要オピニオンリーダーの見解

第12章 SWOT分析

第13章 アンメットニーズ

第14章 市場アクセスと償還

• 米国
• EU4ヶ国と英国
• 日本

第16章 付録

第17章 DelveInsightのサービス内容

第18章 免責事項

第19章 DelveInsightについて

List of Tables

• Table 1 Summary of AN Market and Epidemiology (2020-2034)
• Table 2 Severity Specific Classification
• Table 3 Total Prevalent Cases of Anorexia Nervosa In the 7MM (2020-2034)
• Table 4 Total Diagnosed Prevalent Cases of Anorexia Nervosa in the 7MM (2020-2034)
• Table 5 Total Prevalent Cases of Anorexia Nervosa in the US (2020-2034)
• Table 6 Total Diagnosed Prevalent Cases of Anorexia Nervosa in the US (2020-2034)
• Table 7 Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in the US (2020-2034)
• Table 8 Total Prevalent Cases of Anorexia Nervosa in Germany (2020-2034)
• Table 9 Total Diagnosed Prevalent Cases of Anorexia Nervosa in Germany (2020-2034)
• Table 10 Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Germany (2020-2034)
• Table 11 Total Prevalent Cases of Anorexia Nervosa in France (2020-2034)
• Table 12 Total Diagnosed Prevalent Cases of Anorexia Nervosa in France (2020-2034)
• Table 13 Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in France (2020-2034)
• Table 14 Total Prevalent Cases of Anorexia Nervosa in Italy (2020-2034)
• Table 15 Total Diagnosed Prevalent Cases of Anorexia Nervosa in Italy (2020-2034)
• Table 16 Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Italy (2020-2034)
• Table 17 Total Prevalent Cases of Anorexia Nervosa in Spain (2020-2034)
• Table 18 Total Diagnosed Prevalent Cases of Anorexia Nervosa in Spain (2020-2034)
• Table 19 Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Spain (2020-2034)
• Table 20 Total Prevalent Cases of Anorexia Nervosa in the UK (2020-2034)
• Table 21 Total Diagnosed Prevalent Cases of Anorexia Nervosa in the UK (2020-2034)
• Table 22 Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in the UK (2020-2034)
• Table 23 Total Prevalent Cases of Anorexia Nervosa in Japan (2020-2034)
• Table 24 Total Diagnosed Prevalent Cases of Anorexia Nervosa in Japan (2020-2034)
• Table 25 Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Japan (2020-2034)
• Table 26 Key Cross of Emerging Drugs
• Table 27 Psilocybin Clinical Trial Description2024
• Table 28 Ketamine Clinical Trial Description2024
• Table 29 Key Market Forecast Assumptions for Psilocybin
• Table 30 Market Size of Anorexia Nervosa in the 7MM in USD Million (2020-2034)
• Table 31 Market Size of Anorexia Nervosa by Therapies in the 7MM in USD Million (2020-2034)
• Table 32 United States Market Size of Anorexia Nervosa in the US in USD Million (2020-2034)
• Table 33 Market Size of Anorexia Nervosa by Therapies in the US in USD Million (2020-2034)
• Table 34 Market size of Anorexia Nervosa in Germany in USD Million (2020-2034)
• Table 35 Market Size of Anorexia Nervosa by Therapies in Germany in USD Million (2020-2034)
• Table 36 Market size of Anorexia Nervosa in France in USD Million (2020-2034)
• Table 37 Market Size of Anorexia Nervosa by Therapies in France in USD Million (2020-2034)
• Table 38 Market size of Anorexia Nervosa in Italy in USD Million (2020-2034)
• Table 39 Market Size of Anorexia Nervosa by Therapies in Italy in USD Million (2020-2034)
• Table 40 Market size of Anorexia Nervosa in Spain in USD Million (2020-2034)
• Table 41 Market Size of Anorexia Nervosa by Therapies in Spain in USD Million (2020-2034)
• Table 42 Market size of Anorexia Nervosa in the UK USD Million (2020-2034)
• Table 43 Market Size of Anorexia Nervosa by Therapies in the UK USD Million (2020-2034)
• Table 44 Market Size of Anorexia Nervosa in Japan in USD Million (2020-2034)
• Table 45 Market Size of Anorexia Nervosa by Therapies in Japan USD Million (2020-2034)

List of Figures

• Figure 1 Types of Eating Disorder
• Figure 2 Types of Anorexia Nervosa
• Figure 3 Physical Signs and Effects of Anorexia Nervosa
• Figure 4 Medical Complications
• Figure 5 Psychiatric Comorbidity
• Figure 6 Stepwise approach to managing Anorexia Nervosa
• Figure 7 Key Strategies for Treatment of Anorexia Nervosa
• Figure 8 Phases of FBT
• Figure 9 Phases of FPT
• Figure 10 Anorexia Nervosa Treatment Algorithm
• Figure 11 Total Prevalent Cases of Anorexia Nervosa In the 7MM (2020-2034)
• Figure 12 Total Diagnosed Prevalent Cases of Anorexia Nervosa in the 7MM (2020-2034)
• Figure 13 Total Prevalent Cases of Anorexia Nervosa in the United States (2020-2034)
• Figure 14 Total Diagnosed Prevalent Cases of Anorexia Nervosa in the US (2020-2034)
• Figure 15 Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in the US (2020-2034)
• Figure 16 Total Prevalent Cases of Anorexia Nervosa in Germany (2020-2034)
• Figure 17 Total Diagnosed Prevalent Cases of Anorexia Nervosa in Germany (2020-2034)
• Figure 18 Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Germany (2020-2034)
• Figure 19 Total Prevalent Cases of Anorexia Nervosa in France (2020-2034)
• Figure 20 Total Diagnosed Prevalent Cases of Anorexia Nervosa in France (2020-2034)
• Figure 21 Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in France (2020-2034)
• Figure 22 Total Prevalent Cases of Anorexia Nervosa in Italy (2020-2034)
• Figure 23 Total Diagnosed Prevalent Cases of Anorexia Nervosa in Italy (2020-2034)
• Figure 24 Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Italy (2020-2034)
• Figure 25 Total Prevalent Cases of Anorexia Nervosa in Spain (2020-2034)
• Figure 26 Total Diagnosed Prevalent Cases of Anorexia Nervosa in Spain (2020-2034)
• Figure 27 Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Spain (2020-2034)
• Figure 28 Total Prevalent Cases of Anorexia Nervosa in the UK (2020-2034)
• Figure 29 Total Diagnosed Prevalent Cases of Anorexia Nervosa in the UK (2020-2034)
• Figure 30 Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in the UK (2020-2034)
• Figure 31 Total Prevalent Cases of Anorexia Nervosa in Japan (2020-2034)
• Figure 32 Total Diagnosed Prevalent Cases of Anorexia Nervosa in Japan (2020-2034)
• Figure 33 Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Japan (2020-2034)
• Figure 34 Patient Journey
• Figure 35 Market Size of Anorexia Nervosa in the 7MM, in USD Million (2020-2034)
• Figure 36 Market Size of Anorexia Nervosa by Therapies in the 7MM in USD Million (2020-2034)
• Figure 37 Market Size of Anorexia Nervosa in the United States, USD Million (2020-2034)
• Figure 38 Market Size of Anorexia Nervosa by Therapies in the United States, in USD Million (2020-2034)
• Figure 39 Market size of Anorexia Nervosa in Germany, in USD Million (2020-2034)
• Figure 40 Market Size of Anorexia Nervosa by Therapies in Germany, in USD Million (2020-2034)
• Figure 41 Market size of Anorexia Nervosa in France, in USD Million (2020-2034)
• Figure 42 Market Size of Anorexia Nervosa by Therapies in France, in USD Million (2020-2034)
• Figure 43 Market size of Anorexia Nervosa in Italy, in USD Million (2020-2034)
• Figure 44 Market Size of Anorexia Nervosa by Therapies in Italy, in USD Million (2020-2034)
• Figure 45 Market size of Anorexia Nervosa in Spain, in USD Million (2020-2034)
• Figure 46 Market Size of Anorexia Nervosa by Therapies in Spain, in USD Million (2020-2034)
• Figure 47 Market size of Anorexia Nervosa in UK, in USD Million (2020-2034)
• Figure 48 SWOT Analysis
• Figure 49 Unmet Needs
• Figure 55 Health Technology Assessment
• Figure 56 Reimbursement Process in Germany
• Figure 57 Reimbursement Process in France
• Figure 58 Reimbursement Process in Italy
• Figure 59 Reimbursement Process in Spain
• Figure 60 Reimbursement Process in the United Kingdom

Key Highlights:

• In 2023 the total anorexia nervosa treatment market size in the 7MM was approximately USD 60 million out of which the US accounted for approximately USD 30 million.
• Societal emphasis on thinness and idealized body images in media and culture can contribute to body dissatisfaction and disordered eating behaviors including anorexia nervosa during the forecast period (2024-2034).
• Improved access to mental health services including specialized treatment programs and therapy may result in more individuals receiving a diagnosis of anorexia nervosa. Furthermore, greater awareness of eating disorders along with improved diagnostic criteria and screening methods can lead to more accurate identification of individuals with anorexia nervosa during the forecast period (2024-2034).
• Factors such as population growth aging populations changing demographics may increase the number of individuals affected by anorexia nervosa thereby expanding the potential market size for treatment options.
• There are no US FDA-approved therapies for anorexia the current treatment of anorexia nervosa involves a multidisciplinary approach addressing both physical and psychological aspects and very few companies are even trying to work on this disorder. Observing the increasing cases of anorexia nervosa worldwide there is a huge need for pharmacological therapies that not only suppress the symptoms but also cure the disorder.
• Moreover treating anorexia nervosa requires a multidisciplinary approach involving psychiatrist's psychologist's dieticians and other healthcare professionals. Coordinating these services and ensuring comprehensive care can be challenging, especially in regions with limited resources or fragmented healthcare systems.
• However various therapies are being developed such as Compass Pathway's COMP360 (psilocybin) Homeostasis Therapeutics Ketamine and others that shall further create a positive impact on the market.

DelveInsight's "Anorexia Nervosa Treatment Market Insight Epidemiology and Market Forecast - 2034" report delivers an in-depth analysis of anorexia nervosa epidemiology and clinical development understanding of top oncogenic drivers/biomarkers in anorexia nervosa. In addition, this report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the anorexia nervosa market trends in the United States, EU4 (Germany, Spain, Italy, and France) and United Kingdom, and Japan.

The anorexia nervosa treatment market report provides real-world prescription pattern analysis of emerging drugs assessment market share and uptake/adoption pattern of individual therapies as well as historical and forecasted anorexia nervosa market size from 2020 to 2034 in 7MM. The report also covers current anorexia nervosa treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain), and the United Kingdom
• Japan

Anorexia Nervosa Market

Anorexia Nervosa Overview

Anorexia Nervosa is an eating disorder characterized by weight loss or lack of appropriate weight gain in growing children; difficulties maintaining an appropriate body weight for height and stature; and in many individuals body image. People with Anorexia Nervosa generally restrict the number of calories and the types of food they eat.

This disorder is characterized by deliberate weight loss induced and sustained by the patient. It occurs most commonly in adolescent girls and young women but adolescent boys and young men may also be affected as many children approach puberty and older women up to menopause. The disorder is associated with specific psychopathology whereby a dread of fatness and flabbiness of body contour persists as an intrusive overvalued idea and the patients impose a low weight threshold on themselves. There is usually undernutrition of varying severity with secondary endocrine and metabolic changes and disturbances of bodily function. The symptoms include restricted dietary choice excessive exercise-induced vomiting and purgation use of appetite suppressants and diuretics

Eating disorders are not a choice but are serious mental illnesses and can significantly impact all aspects of a person's life - physical emotional and social. The earlier an eating disorder is identified and a person can access treatment the greater the opportunity for recovery or improved quality of life.

Continued in the report.....

Anorexia Nervosa Diagnosis

No objective test-such as bloodwork or an X-ray-can definitively point to an eating disorder. Instead, a doctor makes the diagnosis based on a person's symptoms. To diagnose anorexia the doctor will ask about the person's symptoms and they may also ask family members and other loved ones about their observations. If a doctor believes that a person has anorexia they will attempt to diagnose the type. One type primarily involves restricting food intake while another involves episodes of overeating and purging. If the person has experienced at least one of these episodes in the past 3 months the doctor will likely diagnose binge eating and purging anorexia.

Diagnostic instruments in the form of questionnaires are used. A few of them are as follows:

• Structured Inventory for Anorexic and Bulimic Eating Disorders Self-Report (SIAB-S)
• Munich Eating and Feeding Disorder Questionnaire (Munich ED-Quest)
• Eating Disorder Examination-Questionnaire for Children (ChEDE-Q)
• The SCOFF questionnaire

Continued in the report.....

Anorexia Nervosa Treatment Market

Anorexia Nervosa (AN) is an eating disorder characterized by weight loss or lack of appropriate weight gain in growing children; difficulties maintaining an appropriate body weight for height age and stature; and in many individuals distorted body image. People with Anorexia Nervosa generally restrict the number of calories and the types of food they eat.

This disorder is characterized by deliberate weight loss induced and sustained by the patient. It occurs most commonly in adolescent girls and young women but adolescent boys and young men may also be affected as many children approach puberty and older women up to menopause. The disorder is associated with specific psychopathology whereby a dread of fatness and flabbiness of body contour persists as an intrusive overvalued idea and the patients impose a low weight threshold on themselves. There is usually undernutrition of varying severity with secondary endocrine and metabolic changes and disturbances of bodily function. The symptoms include restricted dietary choice excessive exercise-induced vomiting and purgation use of appetite suppressants and diuretics Eating disorders are not a choice but are serious mental illnesses and can significantly impact all aspects of a person's life - physical emotional and social. The earlier an eating disorder is identified and a person can access treatment the greater the opportunity for recovery or improved quality of life.

Continued in the report.....

Anorexia Nervosa Epidemiology

As the anorexia nervosa treatment market is derived using a patient-based model the anorexia nervosa epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of anorexia nervosa total diagnosed prevalent cases of anorexia nervosa gender-specific diagnosed prevalent cases of anorexia nervosa in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom and Japan from 2020 to 2034.

• As per DelveInsight analysis in 2023 the total prevalent cases of anorexia nervosa in the 7MM were found to be nearly 1 million out of which approximately 300 thousand cases were identified as diagnosed prevalent cases of anorexia nervosa. These cases are expected to increase during the forecast period (2024-2034) driven by the evolving societal attitudes toward body image weight and beauty standards that may contribute to an increase in disordered eating behaviors including anorexia nervosa in the US.
• Among the EU4 and the UK, Germany had the highest diagnosed prevalent population of anorexia nervosa with approximately 75 thousand cases followed by the UK with around 62 thousand cases in 2023. On the other hand, Spain had the lowest diagnosed prevalent population with nearly 42 thousand cases.
• In 2023, a higher percentage of diagnosed prevalent cases was observed in females than males in all the 7MM countries. Females accounted for a larger proportion of about 92% while males accounted for around 8% of total diagnosed prevalent cases of anorexia nervosa.
• In 2023Japan accounted for about 16% of the total diagnosed prevalent cases of anorexia nervosa out of which roughly 107 thousand cases among females and 4 thousand cases among males. It's anticipated that by 2034 these numbers will change due to alterations in dietary patterns and cultural perceptions of body image in Japan.

Anorexia Nervosa Drugs Chapter

The anorexia treatment drugs chapter segment of the anorexia nervosa report encloses a detailed analysis of anorexia nervosa-marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also helps understand the anorexia nervosa clinical trial details expressive pharmacological action agreements collaboration approval and patent details advantages and disadvantages of each included drug and the latest news and press releases.

Anorexia Nervosa Emerging Drugs

COMP360 (psilocybin): COMPASS Pathways

Psilocybin is a serotonin 2 receptor agonist being developed by COMPASS Pathways for treatment-resistant depression including major depressive disorder depressive disorders bipolar depression body dysmorphic disorder (somatoform disorders in developmental table) and anorexia nervosa. It is an active ingredient in some species of mushrooms often referred to as 'magic mushrooms. Currently, the drug candidate is being investigated in a Phase II (recruiting stage) clinical trial to evaluate the efficacy and safety of COMP360 psilocybin therapy in anorexia nervosa. Additionally, COMP360 is being investigated in post-traumatic stress disorder.

Ketamine: Homeostasis Therapeutics

Ketamine has rapid antidepressant effects which are hypothesized to occur via increases in glutamate with sequelae including increased neuroplasticity neurogenesis and synaptogenesis. It is an N-methyl-D-aspartate receptor (NMDAr) antagonist recently been approved for treatment-resistant depression exerting rapid and robust antidepressant effects. The drug candidate has completed Phase I for anorexia nervosa treatment and is also being investigated for several indications including obsessive-compulsive post-traumatic and substance use disorder and shows diagnostic potential, particularly among clinical non-responders.

Anorexia Treatment Drugs Class Insight

Pharmacological interventions although not FDA-approved specifically for anorexia nervosa are sometimes employed as adjunctive therapies targeting comorbid conditions or specific symptoms linked to the disorder. For instance, antidepressants like selective serotonin reuptake inhibitors (SSRIs) are commonly used to address mood disorders such as depression and anxiety and are often seen alongside anorexia nervosa. Appetite stimulants like mirtazapine may aid in promoting weight gain and restoring appetite in individuals with the disorder. Additionally, gastrointestinal drugs such as prokinetic agents (metoclopramide or domperidone) might be prescribed to manage issues like delayed gastric emptying associated with anorexia nervosa.

Anorexia Nervosa Treatment Market Outlook

Anorexia Nervosa has a diverse genetic disposition as well as being determined by life phases such as puberty problems in the family or peers trauma and personality traits such as low self-esteem. It is characterized by extreme food restriction and an intense fear of gaining weight. Treatment usually involves several strategies including psychological therapy nutritional counseling and/or hospitalization.

Treatment plans are tailored to individual needs and may include one or more of the following:

• The individual group and/or family psychotherapy
• Medical care and monitoring
• Nutritional counseling
• Medications

Psychotherapies generally include Family-based treatment (FBT)Eating disorder-focused Adolescent-focused psychotherapy and others

Medications such as antidepressants antipsychotics or mood stabilizers may also be helpful for the treatment of eating disorders and other co-occurring illnesses such as anxiety or depression. Medications like olanzapine aripiprazole is generally used to manage the patients there is no standard therapy available. Quetiapine is an atypical antipsychotic that in low doses can help with both psychological and physical improvements with minimal associated side effects and appears to be a promising candidate for the treatment of AN. Prozac can help with depressive symptoms and potentially with healthy weight maintenance once weight restoration is achieved. Prozac is part of the SSRI family or the selective serotonin uptake inhibitors that assist with increased serotonin levels connected to mood.

Nonetheless, the anticipated release of promising treatments like COMP360 (psilocybin) Ketamine, and others is anticipated to positively influence the market size throughout the forecast period [2024-2034].

• According to DelveInsight, the Anorexia Nervosa treatment market dynamics of anorexia nervosa are anticipated to change during the forecast period (2024-2034) owing to the expected launch of emerging therapies and increased awareness of mental health issues including eating disorders like anorexia nervosa that may lead to greater recognition and diagnosis of the condition.
• In 2023 the total market size of anorexia nervosa in the 7MM was approximately USD 60 million out of which the US accounted for approximately USD 30 million.
• Among the EU4 and the UK, Germany holds the highest market size of around 25% followed by Italy, and France with approximately 20% each. These numbers are expected to change during the forecast period (2024-2034) driven by the ongoing research and development efforts that may lead to the discovery of more effective medications and therapies for treating anorexia nervosa.
• The anorexia nervosa market size in Japan accounted for nearly 12% of the total 7MM market size in 2023 these numbers are expected to change by 2034 due to the shifts in cultural attitudes towards body image and eating habits that may lead to a higher prevalence of anorexia nervosa in Japan.

Anorexia Nervosa Uptake

The Anorexia Nervosa drugs section focuses on the uptake rate of potential drugs expected to be launched in the market during 2020-2034. For example, COMPASS Pathway's Psilocybi, a serotonin 2 receptor agonist and a psychedelic may provide a much-needed therapeutic breakthrough in anorexia nervosa.

Anorexia Nervosa Pipeline Development Activities

The Anorexia Nervosa teatment market report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I. It also analyzes key players involved in developing targeted therapeutics.

Pipeline development activities

The Anorexia Nervosa treatment market report covers information on collaborations, acquisitions and mergers, licensing, and patent details for emerging therapies for anorexia nervosa.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on anorexia nervosa's evolving treatment landscape patient reliance on conventional therapies patient therapy switching acceptability and drug uptake along with challenges related to accessibility including Medical/scientific writers Medical Professionals Professors Directors, and Others.

DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers like the University of Washington, University of Colorado School, University Hospital Tuebingen, University Hospital of the RWTH, University Hospital of Bellvitge, University College London, and Kyoto Prefectural University of Medicine were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or anorexia nervosa market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Physician's View

According to physicians treatment for anorexia must address both psychological and physical problems. The treatment team should include a mental health professional and a primary care doctor.

Successful treatment usually includes continuous medical care regular therapy nutritional counseling and medication. Although certain antidepressants are sometimes used to treat anorexia they are not always effective and no medication is US FDA-approved to treat it. Therefore physicians should pay attention to bone loss electrolyte levels in the blood and heart function. Psychologists and other mental health professionals can help a person let go of self-destructive thoughts and behaviors and adopt a more positive outlook. Support groups of other recovering anorexics -- when properly moderated by a mental health professional -- can also be very helpful. Treatment usually is successful but it does not work overnight. Long-term psychological and medical attention usually is needed

Anorexia Nervosa Drugs Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches such as SWOT analysis and Attribute Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Attribute Analysis analyzes multiple emerging therapies based on relevant attributes such as safety efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in anorexia nervosa trials one of the most important primary outcome measures is complete eschar removal.

Further, the therapies' safety is evaluated wherein the acceptability tolerability, and adverse events are majorly observed it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Anorexia Nervosa Treatment Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the Anorexia Nervosa drugs market. Because of the high cost, the economic burden is increasing leading the patient to escape from proper treatment.

The reimbursement challenges related to medical care and treatment for individuals with anorexia nervosa can be significant as they often require specialized medical attention covering the costs of diagnosis treatment and ongoing care. Health insurance plans may not fully cover limited coverage of some medical treatments and therapies specific to anorexia nervosa. This can result in high out-of-pocket expenses for families seeking the best care for their loved ones. Moreover, it requires specialized care from healthcare providers with expertise. Finding and accessing such specialists may be challenging, and the associated costs may not always be fully reimbursed by insurance.

Scope of the Anorexia Nervosa Treatment tMarket Report

• The Anorexia Nervosa Treatment Market Report covers a segment of key events executive summary descriptive overview of anorexia nervosa, explaining its causes and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts the future growth potential of diagnosis rate disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and emerging therapies along with the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the anorexia nervosa market's historical and forecasted market size market share by therapies, detailed assumptions, and rationale behind our approach is included in the report covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM anorexia nervosa market.

Anorexia Nervosa Drugs report insights

• Patient Population
• Therapeutic Approaches
• Anorexia Nervosa Pipeline Analysis
• Anorexia Nervosa Market Size and Trends
• Existing and Future Market Opportunity

Anorexia Nervosa reports key strengths

• 11 years Forecast for Anorexia Nervosa Drugs
• The 7MM Coverage for Anorexia Treatment Drugs
• Anorexia Nervosa Epidemiology Segmentation
• Key Cross Competition
• Attribute analysis of Anorexia Nervosa Treatment Market
• Anorexia Nervosa Drugs Uptake
• Key Anorexia Nervosa Market Forecast Assumptions

Anorexia Nervosa Treatment Market report assessment

• Current Anorexia Nervosa Treatment Practices
• Anorexia Nervosa Unmet Needs
• Anorexia Nervosa Pipeline Product Profiles
• Anorexia Nervosa Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)
• Anorexia Nervosa Market Drivers
• Anorexia Nervosa Barriers

Key Questions Answered In The Anorexia Nervosa Market Report:

Anorexia Nervosa Treatment Market Insights

• What was the total market size of anorexia nervosa, the market size of anorexia nervosa by therapies, and market share (%) distribution in 2020, and what would it look like by 2034? What are the contributing factors for this growth?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest anorexia nervosa market size during the forecast period (2024-2034)?
• How will Psilocybin affect the treatment paradigm of anorexia nervosa?
• Psilocybin is going to be the largest contributor by 2034.
• What are the pricing variations among different geographies for upcoming therapies?
• How would future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Anorexia Nervosa Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of anorexia nervosa?
• What will be the growth opportunities across the 7MM concerning the patient population about anorexia nervosa?
• What is the historical and forecasted anorexia nervosa patient pool in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?
• Out of the countries mentioned above, which country would have the highest diagnosed prevalent anorexia nervosa population during the forecast period (2024-2034)?
• What factors are contributing to the growth of anorexia nervosa cases?

Current Anorexia Nervosa Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for the treatment of anorexia nervosa? What are the current clinical and treatment guidelines for treating anorexia nervosa?
• How many companies are developing therapies for the treatment of anorexia nervosa?
• How many emerging therapies are in the mid-stage and late stage of development for treating anorexia nervosa?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What is the cost burden of current treatment on the patient?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the accessibility issues of approved therapy in the US?
• What is the 7MM historical and forecasted market of anorexia nervosa?

Reasons to Buy Anorexia Nervosa Market Report

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the anorexia nervosa market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• The distribution of historical and current patient share is based on real-world prescription data in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying upcoming solid players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies for anorexia nervosa, barriers to accessibility of approved therapy, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1 Key Insights

2 Report Introduction

3 Anorexia Nervosa Market Overview at a Glance

• 3.1. Market Share (%) Distribution of Anorexia Nervosa by Therapies in 2020
• 3.2. Market Share (%) Distribution of Anorexia Nervosa by Therapies in 2034

4 Anorexia Nervosa Market: Future Perspective

5 Executive Summary of Anorexia nervosa

6 Disease Background and Overview: Anorexia Nervosa (AN)

• 6.1. Introduction of Anorexia Nervosa
• 6.2. Types of Anorexia Nervosa
• 6.3. Risk factors of Anorexia Nervosa
• 6.4. Symptoms of Anorexia Nervosa
• 6.5. Comorbidities of Anorexia Nervosa
• 6.6. Etiology of Anorexia Nervosa
• 6.7. Pathophysiology of Anorexia Nervosa
• 6.8. Diagnostic Approach of Anorexia Nervosa
  • 6.8.1. Diagnostic Guidelines
    • 6.8.1.1. DSM-5 Diagnostic Criteria
    • 6.8.1.2. ICD-11 diagnostic criteria (6B10)
    • 6.8.1.3. ICD-10 diagnostic criteria (FB50.0)
    • 6.8.1.4. German Guidelines on Fluency Disorders based on ICF mode
• 6.9. Treatment and Management of Anorexia Nervosa
  • 6.9.1. Treatment Algorithm
  • 6.9.2. Treatment Guidelines
    • 6.9.2.1. AAFP Key Recommendations:
    • 6.9.2.2. German Guidelines
    • 6.9.2.3. WFSBP Guidelines for the Pharmacological Treatment of Eating Disorders
    • 6.9.2.4. APA Practice Guidelines
    • 6.9.2.5. NICE Guidelines

7 Epidemiology and Patient Population

• 7.1. Key Findings
• 7.2. Methodology of Epidemiology
• 7.3. Assumptions and Rationale: 7MM
• 7.4. Total Prevalent Cases of Anorexia Nervosa in the 7MM
• 7.5. Total Diagnosed Prevalent Cases of Anorexia Nervosa in the 7MM
• 7.6. The US
  • 7.6.1. Total Prevalent Cases of Anorexia Nervosa in the US
  • 7.6.2. Total Diagnosed Prevalent Cases of Anorexia Nervosa in the US
  • 7.6.3. Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in the US
• 7.7. Major Five European Countries
  • 7.7.1 Germany
    • 7.7.1.1 Total Prevalent Cases of Anorexia Nervosa in Germany
    • 7.7.2.2 Total Diagnosed Prevalent Cases of Anorexia Nervosa in Germany
    • 7.7.3.3 Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Germany
  • 7.7.2 France
    • 7.7.2.1 Total Prevalent Cases of Anorexia Nervosa in France
    • 7.7.2.2 Total Diagnosed Prevalent Cases of Anorexia Nervosa in France
    • 7.7.2.3 Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in France
  • 7.7.3 Italy
    • 7.7.3.1 Total Prevalent Cases of Anorexia Nervosa in Italy
    • 7.7.3.2 Total Diagnosed Prevalent Cases of Anorexia Nervosa in Italy
    • 7.7.3.3 Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Italy
  • 7.7.4 Spain
    • 7.7.4.1 Total Prevalent Cases of Anorexia Nervosa in Spain
    • 7.7.4.2 Total Diagnosed Prevalent Cases of Anorexia Nervosa in Spain
    • 7.7.4.3 Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Spain
  • 7.7.5 UK
    • 7.7.5.1 Total Prevalent Cases of Anorexia Nervosa in the UK
    • 7.7.5.2 Total Diagnosed Prevalent Cases of Anorexia Nervosa in the UK
    • 7.7.5.3 Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in the UK
• 7.8. Japan
  • 7.8.1. Total Prevalent Cases of Anorexia Nervosa in Japan
  • 7.8.2. Total Diagnosed Prevalent Cases of Anorexia Nervosa in Japan
  • 7.8.3. Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Japan

8 Patient Journey

9 Emerging Drugs

• 9.1. Key Cross Competition
• 9.2. Psilocybin: COMPASS Pathways
  • 9.2.1. Product Description
  • 9.2.2. Other Development Activities
  • 9.2.3. Clinical Development
  • 9.2.4. Clinical Trials Information
  • 9.2.5. Safety and Efficacy
  • 9.2.6. Product Profile
  • 9.2.7. Analysts' Views
• 9.3. Ketamine: Homeostasis Therapeutics
  • 9.3.1. Product Description
  • 9.3.2. Other Development Activities
  • 9.3.3. Clinical Development
  • 9.3.4. Clinical Trials Information
  • 9.3.5. Product Profile

10 Anorexia nervosa: 7MM Analysis

• 10.1. Key Findings
• 10.2. Methodology of Anorexia nervosa Market
• 10.3. Market Outlook
• 10.4. Attribute Analysis
• 10.5. Key Market Forecast Assumptions
• 10.6. Total Market Size of Anorexia Nervosa in the 7MM
• 10.7. Total Market Size of Anorexia Nervosa by Therapies in the 7MM
• 10.8. Total Market Size of Anorexia Nervosa in the US
  • 10.8.1. Total Market Size of Anorexia Nervosa by Therapies in the US
  • 10.8.2. Total Market Size of Anorexia Nervosa in Germany
• 10.9. Total Market Size of Anorexia Nervosa by Therapies in Germany
  • 10.9.1. Market Size of Anorexia Nervosa in Spain
    • 10.9.1.1. Total Market Size of Anorexia Nervosa in Spain
    • 10.9.1.2. Market Size of Anorexia Nervosa in France
  • 10.9.2. Total Market Size of Anorexia Nervosa in France
    • 10.9.2.1. Market Size of Anorexia Nervosa in Italy
    • 10.9.2.2. Total Market Size of Anorexia Nervosa in Italy
  • 10.9.3. Market Size of Anorexia Nervosa in the UK
    • 10.9.3.1. Total Market Size of Anorexia Nervosa in the UK
    • 10.9.3.2. Market Size of Anorexia Nervosa in Japan
  • 10.9.4. Total Market Size of Anorexia Nervosa in Japan

11 Key Opinion Leaders' Views

12 SWOT Analysis

13 Unmet Needs

14 Market Access and Reimbursement

• 14.1 The United States
  • 14.1.1 Center for Medicare & Medicaid Services (CMS)
• 14.2 EU4 and the UK
  • 14.2.1 Germany
  • 14.2.2 France
  • 14.2.3 Italy
  • 14.2.4 Spain
  • 14.2.5 The United Kingdom
• 14.3 Japan
  • 14.3.1 MHLW

16 Appendix

• 16.1 Bibliography
• 16.2 Acronyms and Abbreviations
• 16.3 Report Methodology

17 DelveInsight Capabilities

18 Disclaimer

19 About DelveInsight